Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain

Tomohiro Takano; Takashi Sato; Ryutaro Kotaki; Saya Moriyama; Shuetsu Fukushi; Masahiro Shinoda; Kiyomi Kabasawa; Nagashige Shimada; Mio Kousaka; Yu Adachi; Taishi Onodera; Kazutaka Terahara; Masanori Isogawa; Takayuki Matsumura; Masaharu Shinkai; Yoshimasa Takahashi

doi:10.1038/s41467-023-37128-1

Nature Communications (Mar 2023)

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain

Tomohiro Takano,
Takashi Sato,
Ryutaro Kotaki,
Saya Moriyama,
Shuetsu Fukushi,
Masahiro Shinoda,
Kiyomi Kabasawa,
Nagashige Shimada,
Mio Kousaka,
Yu Adachi,
Taishi Onodera,
Kazutaka Terahara,
Masanori Isogawa,
Takayuki Matsumura,
Masaharu Shinkai,
Yoshimasa Takahashi

Affiliations

Tomohiro Takano: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Takashi Sato: Tokyo Shinagawa Hospital
Ryutaro Kotaki: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Saya Moriyama: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Shuetsu Fukushi: Department of Virology I, National Institute of Infectious Diseases
Masahiro Shinoda: Tokyo Shinagawa Hospital
Kiyomi Kabasawa: Tokyo Shinagawa Hospital
Nagashige Shimada: Tokyo Shinagawa Hospital
Mio Kousaka: Tokyo Shinagawa Hospital
Yu Adachi: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Taishi Onodera: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Kazutaka Terahara: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Masanori Isogawa: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Takayuki Matsumura: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
Masaharu Shinkai: Tokyo Shinagawa Hospital
Yoshimasa Takahashi: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases

DOI: https://doi.org/10.1038/s41467-023-37128-1
Journal volume & issue: Vol. 14, no. 1
pp. 1 – 13

Abstract

Read online

Takano et al. show that heterologous booster by SARS-CoV-2 recombinant spike protein vaccine recalls a more sustained and broader anti-spike receptor-binding domain antibody response compared to homologous booster by mRNA vaccine.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal